Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 10,977,000 | 10,807,000 | 8,681,000 | 7,983,000 | 8,543,000 |
| Depreciation Amortization | 2,741,000 | 2,087,000 | 2,620,000 | 1,856,000 | 1,345,000 |
| Accounts receivable | 10,000 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -16,000 | N/A | N/A | N/A | N/A |
| Other Working Capital | 82,000 | 1,329,000 | -210,000 | -443,000 | 108,000 |
| Other Operating Activity | -3,114,000 | -2,484,000 | -2,349,000 | -1,886,000 | -2,303,000 |
| Operating Cash Flow | $10,680,000 | $11,739,000 | $8,742,000 | $7,510,000 | $7,693,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -125,000 | N/A | N/A | N/A | N/A |
| PPE Investments | -708,000 | -824,000 | -1,057,000 | -1,076,000 | -759,000 |
| Net Acquisitions | -348,000 | 0 | 0 | -14,891,000 | -1,148,000 |
| Purchase Of Investment | -34,000 | N/A | N/A | N/A | N/A |
| Sale Of Investment | 5,000 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -1,180,000 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -1,016,000 | -1,652,000 | -2,839,000 | 1,080,000 | 1,635,000 |
| Investing Cash Flow | $-2,226,000 | $-2,476,000 | $-3,896,000 | $-14,887,000 | $-272,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -8,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -1,741,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 494,000 | N/A | N/A | N/A | N/A |
| Common Stock Repurchased | -2,604,000 | N/A | N/A | N/A | N/A |
| Dividend Paid | -3,361,000 | -2,977,000 | -2,739,000 | -2,641,000 | -2,220,000 |
| Other Financing Activity | -114,000 | -652,000 | -3,623,000 | 8,692,000 | -3,146,000 |
| Financing Cash Flow | $-7,334,000 | $-3,629,000 | $-6,362,000 | $6,051,000 | $-5,366,000 |
| Exchange Rate Effect | 33,000 | 71,000 | -88,000 | 64,000 | 39,000 |
| Beginning Cash Position | 9,828,000 | 4,123,000 | 5,727,000 | 6,989,000 | 4,895,000 |
| End Cash Position | 10,981,000 | 9,828,000 | 4,123,000 | 5,727,000 | 6,989,000 |
| Net Cash Flow | $1,153,000 | $5,705,000 | $-1,604,000 | $-1,262,000 | $2,094,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 10,680,000 | 11,739,000 | 8,742,000 | 7,510,000 | 7,693,000 |
| Capital Expenditure | -791,000 | N/A | N/A | N/A | N/A |
| Free Cash Flow | 9,889,000 | 11,739,000 | 8,742,000 | 7,510,000 | 7,693,000 |